These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23374867)

  • 1. Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulator.
    Hao J; Dehlinger V; Fivush AM; Rudyk HC; Britton TC; Hollinshead SP; Vokits BP; Clark BP; Henry SS; Massey SM; Peng L; Dressman BA; Heinz BA; Roberts EF; Bracey-Walker MR; Swanson S; Catlow JT; Love PL; Tepool AD; Peters SC; Simmons RM; Iyengar S; McKinzie DL; Monn JA
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1249-52. PubMed ID: 23374867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Phenyl-5-isothiazole carboxamides with potent mGluR1 antagonist activity.
    Fisher MJ; Backer RT; Barth VN; Garbison KE; Gruber JM; Heinz BA; Iyengar S; Hollinshead SP; Kingston A; Kuklish SL; Li L; Nisenbaum ES; Peters SC; Phebus L; Simmons RM; van der Aar E
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2514-7. PubMed ID: 22386665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Acting at Site Distinct from 2-Methyl-6-(phenylethynyl)-pyridine Binding.
    Butkiewicz M; Rodriguez AL; Rainey SE; Wieting J; Luscombe VB; Stauffer SR; Lindsley CW; Conn PJ; Meiler J
    ACS Chem Neurosci; 2019 Aug; 10(8):3427-3436. PubMed ID: 31132237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254).
    Turlington M; Noetzel MJ; Chun A; Zhou Y; Gogliotti RD; Nguyen ED; Gregory KJ; Vinson PN; Rook JM; Gogi KK; Xiang Z; Bridges TM; Daniels JS; Jones C; Niswender CM; Meiler J; Conn PJ; Lindsley CW; Stauffer SR
    J Med Chem; 2013 Oct; 56(20):7976-96. PubMed ID: 24050755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.
    Felts AS; Rodriguez AL; Morrison RD; Venable DF; Manka JT; Bates BS; Blobaum AL; Byers FW; Daniels JS; Niswender CM; Jones CK; Conn PJ; Lindsley CW; Emmitte KA
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5779-85. PubMed ID: 24074843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fused thiazolyl alkynes as potent mGlu5 receptor positive allosteric modulators.
    Packiarajan M; Grenon M; Zorn S; Hopper AT; White AD; Chandrasena G; Pu X; Brodbeck RM; Robichaud AJ
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4037-43. PubMed ID: 23770058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy.
    Nickols HH; Yuh JP; Gregory KJ; Morrison RD; Bates BS; Stauffer SR; Emmitte KA; Bubser M; Peng W; Nedelcovych MT; Thompson A; Lv X; Xiang Z; Daniels JS; Niswender CM; Lindsley CW; Jones CK; Conn PJ
    J Pharmacol Exp Ther; 2016 Jan; 356(1):123-36. PubMed ID: 26503377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor.
    Bartolomé-Nebreda JM; Conde-Ceide S; Delgado F; Iturrino L; Pastor J; Pena MÁ; Trabanco AA; Tresadern G; Wassvik CM; Stauffer SR; Jadhav S; Gogi K; Vinson PN; Noetzel MJ; Days E; Weaver CD; Lindsley CW; Niswender CM; Jones CK; Conn PJ; Rombouts F; Lavreysen H; Macdonald GJ; Mackie C; Steckler T
    J Med Chem; 2013 Sep; 56(18):7243-59. PubMed ID: 23947773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.
    Felts AS; Rodriguez AL; Morrison RD; Bollinger KA; Venable DF; Blobaum AL; Byers FW; Thompson Gray A; Daniels JS; Niswender CM; Jones CK; Conn PJ; Lindsley CW; Emmitte KA
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4858-4866. PubMed ID: 28958625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
    Parmentier-Batteur S; Hutson PH; Menzel K; Uslaner JM; Mattson BA; O'Brien JA; Magliaro BC; Forest T; Stump CA; Tynebor RM; Anthony NJ; Tucker TJ; Zhang XF; Gomez R; Huszar SL; Lambeng N; Fauré H; Le Poul E; Poli S; Rosahl TW; Rocher JP; Hargreaves R; Williams TM
    Neuropharmacology; 2014 Jul; 82():161-73. PubMed ID: 23291536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding Exposure-Receptor Occupancy Relationships for Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators across a Range of Preclinical and Clinical Studies.
    Bennett KA; Sergeev E; MacSweeney CP; Bakker G; Cooper AE
    J Pharmacol Exp Ther; 2021 Apr; 377(1):157-168. PubMed ID: 33541889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects.
    Gould RW; Amato RJ; Bubser M; Joffe ME; Nedelcovych MT; Thompson AD; Nickols HH; Yuh JP; Zhan X; Felts AS; Rodriguez AL; Morrison RD; Byers FW; Rook JM; Daniels JS; Niswender CM; Conn PJ; Emmitte KA; Lindsley CW; Jones CK
    Neuropsychopharmacology; 2016 Mar; 41(4):1166-78. PubMed ID: 26315507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling.
    Noetzel MJ; Gregory KJ; Vinson PN; Manka JT; Stauffer SR; Lindsley CW; Niswender CM; Xiang Z; Conn PJ
    Mol Pharmacol; 2013 Apr; 83(4):835-47. PubMed ID: 23348500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
    Satow A; Maehara S; Ise S; Hikichi H; Fukushima M; Suzuki G; Kimura T; Tanak T; Ito S; Kawamoto H; Ohta H
    J Pharmacol Exp Ther; 2008 Aug; 326(2):577-86. PubMed ID: 18487514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and structure-activity relationship of 1,3-cyclohexyl amide derivatives as novel mGluR5 negative allosteric modulators.
    Zhou H; Topiol SW; Grenon M; Jimenez HN; Uberti MA; Smith DG; Brodbeck RM; Chandrasena G; Pedersen H; Madsen JC; Doller D; Li G
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1398-406. PubMed ID: 23357634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.
    Sengmany K; Hellyer SD; Albold S; Wang T; Conn PJ; May LT; Christopoulos A; Leach K; Gregory KJ
    Neuropharmacology; 2019 May; 149():83-96. PubMed ID: 30763654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles.
    Rook JM; Tantawy MN; Ansari MS; Felts AS; Stauffer SR; Emmitte KA; Kessler RM; Niswender CM; Daniels JS; Jones CK; Lindsley CW; Conn PJ
    Neuropsychopharmacology; 2015 Feb; 40(3):755-65. PubMed ID: 25241804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism.
    Bridges TM; Rook JM; Noetzel MJ; Morrison RD; Zhou Y; Gogliotti RD; Vinson PN; Xiang Z; Jones CK; Niswender CM; Lindsley CW; Stauffer SR; Conn PJ; Daniels JS
    Drug Metab Dispos; 2013 Sep; 41(9):1703-14. PubMed ID: 23821185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.
    Felts AS; Rodriguez AL; Blobaum AL; Morrison RD; Bates BS; Thompson Gray A; Rook JM; Tantawy MN; Byers FW; Chang S; Venable DF; Luscombe VB; Tamagnan GD; Niswender CM; Daniels JS; Jones CK; Conn PJ; Lindsley CW; Emmitte KA
    J Med Chem; 2017 Jun; 60(12):5072-5085. PubMed ID: 28530802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.
    Lindemann L; Jaeschke G; Michalon A; Vieira E; Honer M; Spooren W; Porter R; Hartung T; Kolczewski S; Büttelmann B; Flament C; Diener C; Fischer C; Gatti S; Prinssen EP; Parrott N; Hoffmann G; Wettstein JG
    J Pharmacol Exp Ther; 2011 Nov; 339(2):474-86. PubMed ID: 21849627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.